Reach Us +1-217-403-9671
Regulatory Perspective Of Transdermal Drug Delivery Systems | 7435
ISSN: 2167-7689

Pharmaceutical Regulatory Affairs: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Regulatory perspective of transdermal drug delivery systems

2nd International Conference and Exhibition on Pharmaceutical Regulatory Affairs

C. Kishore and P.K.Lakshmi

Posters: Pharmaceut Reg Affairs

DOI: 10.4172/2167-7689.S1.007

The Regulatory Affairs is a part of the Food and Drug Administration (FDA) that enforces the laws governing biologic, drugs, medical devices, etc. which may have potential side effects for the consumers. Transdermal delivery is used to administer drugs via the skin, for systemic or local use. Transdermal drug delivery represents a promising alternative to oral, intravascular and subcutaneous routes. The first US transdermal drug delivery system (TDDS) was approved by the FDA more than 30 years ago. Despite this length of time and the advancement of science in many other pharmaceutical fields, little has changed or evolved in the development and control of these products. Over the years, various product quality problems have been reported by patients and practitioners. Some of these quality problems have a safety and efficacy implications that have led to the recall of numerous batches of products and, in some cases, the temporary or permanent removal of the product from the market. Regulatory agencies worldwide is constantly raising the bar with more stringent interpretation of existing and new regulations with government increasing focus and attention towards patient safety and costs of health care. The worldwide transdermal delivery market is growing at about $2 billion per year. The yearly U.S. market for transdermal patches is projected to exceed $3- plus billion. Industry analysts predict that the transdermal delivery market will rise from $21.5 billion during 2010 to $31.5 billion in 2015. The present review focuses on different approved polymers, Chronological Events in Transdermal Drug Delivery System and FDA Approvals and more importance is given to Regulatory Requirements for TDDS in U.S U.K, Japan and Asian countries.
C. Kishore completed Bachelors in Pharmacy from Sri Venkateshwara College of Pharmacy affiliated to Osmania University , Hyderabad and now pursuing a Masters in Pharmacy (second semester) from Department of Pharmaceutics, G. Pulla Reddy college of Pharmacy.